Acyclovir Suppressive Therapy
For patients with frequent recurrent genital herpes (≥6 recurrences per year), prescribe acyclovir 400 mg orally twice daily for chronic suppressive therapy, which reduces recurrence frequency by ≥75%. 1, 2
Recommended Dosing Regimen
Standard Suppressive Therapy
- Acyclovir 400 mg orally twice daily is the established regimen 1, 2
- Alternative: Acyclovir 200 mg orally 3-5 times daily (less convenient, use to find minimum effective dose for individual patients) 3
Duration of Therapy
- Continue for up to 12 months, then reassess 2
- After 1 year of continuous suppression, discontinue therapy temporarily to evaluate the patient's recurrence rate, as frequency naturally decreases over time in many patients 1
- Safety and efficacy documented for up to 6 years of continuous use 1
- Long-term suppression (up to 3 years) shows 61% of patients remain recurrence-free in year 3, with annual recurrence rates dropping from >12 to approximately 1.0 per year 4
Renal Impairment Adjustments
Dose modification is mandatory in renal impairment 2:
For 400 mg twice daily regimen:
- CrCl >10 mL/min/1.73m²: 400 mg every 12 hours (no adjustment)
- CrCl 0-10 mL/min/1.73m²: 200 mg every 12 hours
For 800 mg dosing (if used):
- CrCl >25 mL/min/1.73m²: 800 mg every 4 hours, 5x daily
- CrCl 10-25 mL/min/1.73m²: 800 mg every 8 hours
- CrCl 0-10 mL/min/1.73m²: 800 mg every 12 hours
Dialysis Patients:
- Hemodialysis: Administer an additional dose after each dialysis session (acyclovir half-life ~5 hours during dialysis with 60% plasma concentration decrease) 2
- Peritoneal dialysis: No supplemental dose needed after interval adjustment 2
Special Populations
HIV-Infected Patients
- Use twice-daily regimens only (acyclovir 400 mg BID or valacyclovir 500 mg BID) 5
- Single daily dosing is inadequate for HIV-infected individuals
- Suppressive therapy also decreases HIV concentration in plasma and genital secretions 5
- Monitor renal function if patient has substantial renal impairment 5
Pregnancy
- Acyclovir is the first-line choice (most safety data available) 5
- For prophylaxis after 36 weeks gestation: 400 mg three times daily until delivery 6
- Suppressive therapy in late pregnancy reduces need for cesarean section due to active lesions 5
Clinical Efficacy
Suppressive therapy provides substantial benefit:
- Reduces recurrence frequency by 74-93% 7
- 25% of patients receiving 3 years of suppression remain completely recurrence-free 4
- Does NOT eliminate asymptomatic viral shedding or completely prevent transmission 1
- Post-treatment recurrence rates remain lower than pre-treatment baseline 8
Important Caveats
Monitoring Requirements
- No routine laboratory monitoring needed unless substantial renal impairment exists 5
- Maintain adequate hydration 2
- Monitor for nausea or headache (occasional side effects) 5
Treatment Failure
- If recurrences occur during suppression, suspect inadequate dosing 9
- Consider increasing to 200 mg four times daily if breakthrough occurs on twice-daily dosing 8
- If lesions don't resolve within 7-10 days, suspect acyclovir resistance (obtain viral culture and susceptibility testing) 5
Patient Counseling
- Acyclovir is NOT a cure 2
- Transmission can still occur during asymptomatic viral shedding 1
- Avoid sexual contact when lesions or prodromal symptoms present 2
- Use condoms consistently with new or uninfected partners 1
Resistance Concerns
- Clinically significant acyclovir resistance has NOT been associated with suppressive therapy in immunocompetent patients 1
- Resistance more likely in immunocompromised patients 5
Dosing Algorithm Summary
- Confirm indication: ≥6 recurrences per year
- Check renal function: Adjust dose if CrCl <10 mL/min
- Start: Acyclovir 400 mg PO BID
- Reassess at 1 year: Discontinue temporarily to evaluate ongoing need
- If breakthrough recurrences: Consider increasing frequency to 200 mg 4x daily
- Long-term use: Safe for up to 6 years if clinically indicated